Current Options and Future Directions for NAFLD and NASH Treatment
Chunye Zhang,Ming Yang +1 more
TLDR
In this paper, the authors developed non-invasive serum diagnostic markers for fulfilling the need of diagnostic testing in a large amount of NAFLD cases, which is helpful to choose an optimized treatment.Abstract:
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with a broad spectrum ranging from simple steatosis to advanced stage of nonalcoholic steatohepatitis (NASH). Although there are many undergoing clinical trials for NAFLD treatment, there is no currently approved treatment. NAFLD accounts as a major causing factor for the development of hepatocellular carcinoma (HCC), and its incidence rises accompanying the prevalence of obesity and diabetes. Reprogramming of antidiabetic and anti-obesity medicine is a major treatment option for NAFLD and NASH. Liver inflammation and cellular death, with or without fibrosis account for the progression of NAFLD to NASH. Therefore, molecules and signaling pathways involved in hepatic inflammation, fibrosis, and cell death are critically important targets for the therapy of NAFLD and NASH. In addition, the avoidance of aberrant infiltration of inflammatory cytokines by treating with CCR antagonists also provides a therapeutic option. Currently, there is an increasing number of pre-clinical and clinical trials undergoing to evaluate the effects of antidiabetic and anti-obesity drugs, antibiotics, pan-caspase inhibitors, CCR2/5 antagonists, and others on NAFLD, NASH, and liver fibrosis. Non-invasive serum diagnostic markers are developed for fulfilling the need of diagnostic testing in a large amount of NAFLD cases. Overall, a better understanding of the underlying mechanism of the pathogenesis of NAFLD is helpful to choose an optimized treatment.read more
Citations
More filters
Journal ArticleDOI
Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma
TL;DR: Interestingly, the three different arms of the ER stress signaling pathways have been shown to drive chemoresistance in several tumors and could therefore form a promising therapeutic target.
Journal ArticleDOI
The Related Metabolic Diseases and Treatments of Obesity
TL;DR: Prevention and early treatment of obesity are the best options to prevent its progression to many comorbidities and psychological management, especially for patients with obesity and distress, is a good option.
Journal ArticleDOI
A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases
TL;DR:
Journal ArticleDOI
Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity
TL;DR: In this article, the potential effect of ASTN on a diet-induced NASH and liver fibrosis, as well as the underlying cellular and molecular mechanisms were investigated, and it was shown that ASTN treatment significantly inhibited the expression of proinflammatory cytokines and chemokine CCL2 in macrophages in response to lipopolysaccharide (LPS) stimulation.
Journal ArticleDOI
Effects of Dietary α-Linolenic Acid Treatment and the Efficiency of Its Conversion to Eicosapentaenoic and Docosahexaenoic Acids in Obesity and Related Diseases
TL;DR: In this article , the effects of dietary supplementation with alpha-linolenic acid (ALA) in obesity and related diseases are discussed. But, the authors focus on the metabolic conversion of ALA to long-chain n−3 polyunsaturated fatty acids (PUFAs) and do not consider the effect of omega-3 index.
References
More filters
Journal ArticleDOI
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Paul Angulo,Jason M. Hui,Giulio Marchesini,Ellisabetta Bugianesi,Jacob George,Geoffrey C. Farrell,Felicity Enders,Sushma Saksena,Alastair D. Burt,John P. Bida,Keith D. Lindor,Schuyler O. Sanderson,Marco Lenzi,Leon A. Adams,James G. Kench,Terry M. Therneau,Christopher P. Day +16 more
TL;DR: A simple scoring system accurately separates patients with nonalcoholic fatty liver disease with and without advanced fibrosis, rendering liver biopsy for identification ofAdvanced fibrosis unnecessary in a substantial proportion of patients.
Journal ArticleDOI
Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects.
TL;DR: Consequences of research participation for behaviors being investigated do exist, although little can be securely known about the conditions under which they operate, their mechanisms of effects, or their magnitudes.
Journal ArticleDOI
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population
Giorgio Bedogni,Stefano Bellentani,L. Miglioli,Flora Masutti,Marilena Passalacqua,A. Castiglione,Claudio Tiribelli +6 more
TL;DR: FLI is simple to obtain and may help physicians select subjects for liver ultrasonography and intensified lifestyle counseling, and researchers to select patients for epidemiologic studies, but validation of FLI in external populations is needed before it can be employed for these purposes.
Journal ArticleDOI
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam,Philip N. Newsome,Shiv Kumar Sarin,Quentin M. Anstee,Giovanni Targher,Manuel Romero-Gómez,Shira Zelber-Sagi,Vincent Wai-Sun Wong,Jean-François Dufour,Jörn M. Schattenberg,Takumi Kawaguchi,Marco Arrese,Luca Valenti,Gamal Shiha,Claudio Tiribelli,Hannele Yki-Järvinen,Jian-Gao Fan,Henning Grønbæk,Yusuf Yilmaz,Helena Cortez-Pinto,Claudia P. Oliveira,Pierre Bedossa,Leon A. Adams,Ming-Hua Zheng,Yasser Fouad,Wah-Kheong Chan,Nahum Méndez-Sánchez,Sang Hoon Ahn,Laurent Castera,Elisabetta Bugianesi,Vlad Ratziu,Jacob George +31 more
TL;DR: A panel of international experts from 22 countries propose a new definition of metabolic-dysfunction-associated fatty liver disease that is both comprehensive yet simple for the diagnosis of MAFLD and is independent of other liver diseases.
Journal ArticleDOI
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.
Anaïs Vallet-Pichard,Anaïs Vallet-Pichard,Vincent Mallet,Vincent Mallet,Bertrand Nalpas,Bertrand Nalpas,Virginie Verkarre,Antoine Nalpas,Valérie Dhalluin-Venier,Hélène Fontaine,Hélène Fontaine,Stanislas Pol,Stanislas Pol +12 more
TL;DR: For values outside 1.45‐3.25, the FIB‐4 index is a simple, accurate, and inexpensive method for assessing liver fibrosis and proved to be concordant with FibroTest results.